Loading...
XJPX
4594
Market cap29mUSD
Jul 10, Last price  
50.00JPY
1D
2.04%
1Q
-21.88%
Jan 2017
-92.80%
IPO
-87.37%
Name

BrightPath Biotherapeutics Co Ltd

Chart & Performance

D1W1MN
XJPX:4594 chart
P/E
—
P/S
58,279.22
EPS
—
Div Yield, %
—
Shrs. gr., 5y
18.58%
Rev. gr., 5y
-49.29%
Revenues
84k
-92.59%
933,388,000821,625,000822,556,000529,611,999354,410,000155,808,00011,300,0002,504,00015,408,0005,280,00072,0001,133,00084,000
Net income
-1.30b
L+13.36%
17,485,000-412,435,000-994,464,000-1,113,661,000-1,577,142,000-1,884,318,000-1,857,774,000-1,719,634,000-1,484,192,000-1,485,633,000-1,168,082,000-1,151,149,000-1,304,951,000
CFO
-1.37b
L+9.24%
37,487,000-447,198,000-908,711,000-1,067,512,000-1,591,336,000-1,457,571,000-1,784,461,000-1,769,848,000-1,512,022,000-1,204,401,000-1,156,920,000-1,250,359,000-1,365,851,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

BrightPath Biotherapeutics Co., Ltd. specializes in the development of innovative cancer immunotherapies. Among its leading candidates is GRN-1201, currently undergoing Phase II clinical studies for non-small cell lung cancer and Phase I studies for melanoma. The company's diverse development portfolio further encompasses BP1101, a neoantigen vaccine; BP1209, a platform for personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. Other therapeutic avenues include an induced pluripotent stem cell (iPSC)-derived regenerated NKT cell therapy aimed at head and neck cancer, and BP2301, an autologous HER2 chimeric antigen receptor-T (CAR-T) cell therapy targeting solid tumor sarcomas. Beyond its clinical-stage assets, BrightPath Biotherapeutics is also engaged in early-stage discovery efforts for new antibodies, including BP1200, which targets CD73; BP1210, an immune checkpoint inhibitor; and additional antibody candidates such as BP1202, BP1206, and BP1211. Established in Tokyo, Japan, in 2003, the company operated as GreenPeptide Co., Ltd. until its rebranding to BrightPath Biotherapeutics Co., Ltd. in July 2017.
URL
https://www.brightpathbio.com/
IPO date
Oct 22, 2015
Employees
42
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT